Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2021 | Story Dr Nitha Ramnath

A passion for evidence-based medicine and the notion of value in healthcare is what drives Dr Anchen Laubscher, our guest in the fifth episode of the Voices from the Free State podcast. Anchen is driven to ensure that healthcare is scientifically proven, of high quality, cost effective, and tailored to a patient’s needs.  

François van Schalkwyk and Keenan Carelse, UFS alumni leading the university’s United Kingdom Alumni Chapter, have put their voices together to produce and direct the podcast series.  Intended to reconnect alumni with the university and their university experience, the podcasts will be featured on the first Monday of every month, ending in November 2021.  Our featured alumni share and reflect on their experiences at the UFS, how it has shaped their lives, and relate why their ongoing association with the UFS is still relevant and important. The podcasts are authentic conversations – they provide an opportunity for the university to understand and learn about the experiences of its alumni and to celebrate the diversity and touchpoints that unite them.

 

 

Google Podcasts BadgeRSS Podcasts Logo

 

Our podcast guest

Anchen joined Netcare in 2007 as an aeromedical doctor and has been with the group for almost 14 years. As Group Medical Director of Netcare Ltd, Anchen is responsible for the strategic oversight and operational execution of all clinical and quality-related matters across the different divisions of Netcare. Leading a team of subject matter experts, Anchen oversees the group’s key deliverables related to the value of care, encompassing quality outcomes, patient safety, patient experience, and episode cost efficiency, with all components of ‘value’ digitally enabled and data driven.

Anchen is a member of the Hospital Association of South Africa (HASA) subcommittee for Clinical Quality and the South African Committee of Medical Deans (SACOMD) initiative, which was constituted to address the human resource dilemma specifically related to the training of doctors in South Africa. She is a Council member of the University of the Free State, where she also serves on the Senate and holds director appointments in the Mother and Child Academic Hospital (MACAH) Foundation, the My Walk My Soul collaboration between Netcare and Adcock-Ingram and the University of Cape Town Medical Centre Ltd.  Anchen played a pioneering leadership role in South Africa’s response to the 2014 global Ebola Virus Disease (EVD) outbreak, which continues in her role as Gold Command in Netcare and as member of various national committee and advisory structures related to the COVID-19 pandemic preparedness and response. For her role in the South African EVD response, she was recognised with an honorary award from the South African Military Health Services (SAMHS).

Clinically, Anchen continues to contribute to the specialty of emergency medicine, specifically pre-hospital and aeromedicine. She continues to be involved at her alma mater through ad hoc lecturing in electives, research support at GIBS, and participating in health-care courses and conferences such as the 2020 Healthcare Industry Update and Innovation Conference.

Stay tuned for episode six to be released on 5 July 2021.

For further information regarding the podcast series, or to propose other alumni guests, please email us at alumnipodcast@ufs.ac.za

Listen to all the Voices from the Free State podcasts.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept